Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK and Safety of Lifitegrast vs Xiidra in Healthy Subjects
NCT07040826Phase 1Completed
- Sponsor
- Qilu Pharmaceutical
- Start
- Dec 2022
- Primary completion
- Dec 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of lifitegrast in dry eye disease (DED) (2 arms), sponsored by Qilu Pharmaceutical. Primary endpoints: Peak Plasma Concentration at Day 8, Area Under the Plasma Concentration-Time Curve (AUC0-∞) at Day 8 and 5 more. Started Dec 2022; status: completed.
02
Drugs
lifitegrast
03
Conditions
dry eye disease (DED)
Beyond the preview
Go deeper on NCT07040826.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07040826.